Haloperidol should be used sparingly [7] (multiple letters)

Critical Care Medicine

Volumn 30, Issue 11, 2002, Pages 2613-2614

  Skrobik, Yoanna ^a   Fraser, Gilles L ^a   Coursin, Douglas B ^a   Riker, Richard R ^a   Jacobi, Judi ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYROPHENONE DERIVATIVE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; METOCLOPRAMIDE; PHENOTHIAZINE DERIVATIVE; NEUROLEPTIC AGENT;

DELIRIUM; DIFFERENTIAL DIAGNOSIS; DRUG INDICATION; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTENSIVE CARE; LETTER; LONG QT SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; TORSADE DES POINTES; NOTE; PRACTICE GUIDELINE; UNITED STATES;

ANTIPSYCHOTIC AGENTS; DELIRIUM; HALOPERIDOL; HUMANS; PRACTICE GUIDELINES; UNITED STATES;

EID: 0036852037     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200211000-00051     Document Type: Letter

References (0)